Clinical Trial: Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07819214) titled 'Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI' on Sept. 08.

Brief Summary: This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: CLL CLL (Chronic Lymphocytic Leukemia) Chronic Lymphocytic Leukemia (CLL) BTKi

Intervention: DRUG: Epcoritamab

Interventional Arm

Recruitment Status: NOT_YET_RECRUITING

Sponsor: University of California, Irvine

Information provided by (Responsible Party): Catherine Coombs, U...